Gaceta medica de Mexico · 2009
[Prevalence of VHB and VHC serological markers among blood donors in the capital state of Veracruz, Mexico].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Valerio-Ureña Joaquín, Vásquez-Fernández Francisco, Pérez-Sosa Julio A, Cortazar-Benitez Luis F, Chávez-Tapia Norberto C, Ruvalcaba-Rojas Oscar A, Torres-Medina Verónica, Ocejo-Rodríguez Agustín
Аннотация
BACKGROUND: Chronic liver disease has a high mortality among the Mexican population. However epidemiological data on hepatitis B (HBV) and hepatitis C (HCV) infection in the southeast areas of the country is limited. Our objective was to report the prevalence of blood markers of HBV and HCV among blood donors from the capital city of Veracruz, Mexico.
METHODS: Between January and December 2005 we analyzed the results of the screening tests used to detect serological markers of HBV and HCV infection (HBsAg and anti-HCV). We included demographic data of blood donors from the State Center for Blood Transfusion of the capital city of Veracruz.
RESULTS: We reviewed 8,650 blood donor reports and found a prevalence of 0.057% and 1.1% for AgsHB and anti-HCV respectively. Only 2.97% of all individuals with a positive test had been previously screened for hepatic viruses.
CONCLUSIONS: Results from our study indicate that the central and southeast regions of the state of Veracruz have a high anti-HCV prevalence among blood donors when compared with results from other states in Mexico. Further studies should evaluate risk factors in regions with high HCV seropositivity.
METHODS: Between January and December 2005 we analyzed the results of the screening tests used to detect serological markers of HBV and HCV infection (HBsAg and anti-HCV). We included demographic data of blood donors from the State Center for Blood Transfusion of the capital city of Veracruz.
RESULTS: We reviewed 8,650 blood donor reports and found a prevalence of 0.057% and 1.1% for AgsHB and anti-HCV respectively. Only 2.97% of all individuals with a positive test had been previously screened for hepatic viruses.
CONCLUSIONS: Results from our study indicate that the central and southeast regions of the state of Veracruz have a high anti-HCV prevalence among blood donors when compared with results from other states in Mexico. Further studies should evaluate risk factors in regions with high HCV seropositivity.